Modality
Gene Editing
MOA
VEGFi
Target
MALT1
Pathway
T-cell
RCCCRCRB
Development Pipeline
Preclinical
~Dec 2017
→ ~Mar 2019
Phase 1
~Jun 2019
→ ~Sep 2020
Phase 2
Dec 2020
→ Apr 2031
Phase 2Current
NCT06970066
1,647 pts·RB
2025-12→2031-04·Not yet recruiting
NCT08200124
1,200 pts·CRC
2020-12→TBD·Recruiting
2,847 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-04-035.0y awayPh2 Data· RB
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2
Recruit…
P2
Not yet…
Catalysts
Ph2 Data
2031-04-03 · 5.0y away
RB
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06970066 | Phase 2 | RB | Not yet recr... | 1647 | PASI75 |
| NCT08200124 | Phase 2 | CRC | Recruiting | 1200 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 |